Advertisement
Prices at hospitals in monopoly markets are 15 percent higher than those at hospitals in areas with at least four providers

Higher Hospital Prices in U.S. ‘Monopoly Markets’

0
Hospital prices positively associated with indicators of hospital market power
From 2001 to 2009 there was an increase in childhood asthma prevalence

Increase in Child Asthma Has Ceased Overall, but Not for Poor

0
Increase in prevalence from 2001 to 2009, which plateaued then decreased in 2013
Comprehensive cigarette bans are most effective at limiting smoking among casual users

Both Smoking Bans and Cigarette Taxes Deter Smokers

0
Bans seem better for social smokers; heavy smokers primarily deterred by taxes
For patients with pulmonary arterial hypertension

Selexipag Linked to Reduced Risk of Death, Complications in PAH

0
Reduced risk of composite of death or pulmonary arterial hypertension-linked complications
In order to prevent denials

Specific, Consistent ICD-10 Coding Key to Timely Payments

0
Tips to prevent denials include checking EHR selection against documentation, being specific
A minority of patients discharged with chronic obstructive pulmonary disease receive pharmacologic treatment for tobacco use

Few Get Rx to Help Quit Smoking After COPD Hospitalization

0
Treatment not associated with cessation at six to 12 months; differences between medications
Uptravi (selexipag) has been approved by the U.S. Food and Drug Administration to treat adults with pulmonary arterial hypertension.

FDA Approves Uptravi for Pulmonary Arterial Hypertension

0
Drug found to limit worsening of the disease and reduce the need for hospitalization
For patients with acute myeloid leukemia

Daily Spirometry Can Give Early Warning of Pneumonia in AML

0
Patient-performed daily spirometry effective for early identification in patients with acute myeloid leukemia
Implementation of the Affordable Care Act has improved access to care and affordability of care for many adults

Affordable Care Act Has Improved Access to Care, Affordability

0
However, gaps in access to care and affordability still seen, especially for low-income adults
Pembrolizumab (Keytruda) may extend survival for patients with advanced non-small-cell lung cancer

Pembrolizumab Shows Promise in Metastatic NSCLC

0
In study, the immune-based therapy beat docetaxel with fewer side effects